Rhythm Pharmaceuticals, Inc. (RYTM) Cash Flow Statement
Rhythm Pharmaceuticals, Inc. (RYTM) generated -$105.3M of operating cash flow over the twelve months to 2026-06-30, spent $953000 on capital expenditure and had free cash flow of -$106.3M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
RYTMRhythm Pharmaceuticals, Inc.Follow RYTM — free
—
Price chart with a free account
- Market cap
- 6.1B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 3 Nov, in 10 days
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -146.0 | -173.4 | -136.2 | -113.9 | -115.7 | -105.3 | |
| Capital expenditure | 0.4 | 0.3 | 0.0 | 0.0 | 1.0 | -1.0 | |
| Free cash flow | -146.4 | -173.7 | -136.2 | -113.9 | -116.6 | -106.3 | |
| Stock-based compensation | 20.8 | 19.8 | 32.6 | 39.7 | 66.8 | — |
USD millions · SEC XBRL
Rhythm Pharmaceuticals, Inc. — questions
- What is Rhythm Pharmaceuticals, Inc.'s operating cash flow?
- -$105.3M over the twelve months to 2026-06-30.
- How much does Rhythm Pharmaceuticals, Inc. spend on capital expenditure?
- $953000 over the twelve months to 2026-06-30.
- What is Rhythm Pharmaceuticals, Inc.'s free cash flow?
- -$106.3M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Rhythm Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.